(Q34578850)

English

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

expanded access

1 reference

based on heuristic

inferred from title

4

object named as

Axel Le Cesne

0 references

1

object named as

Jean-Yves Blay

0 references

Isabelle Ray-Coquard

3

object named as

Isabelle Ray-Coquard

0 references

object named as

Nicolas Penel

19

0 references

Philippe Alexandre Cassier

12

object named as

Philippe Cassier

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Loïc Chaigneau

11

object named as

Loic Chaigneau

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

15

object named as

Olfa Derbel

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nicolas Isambert

10

object named as

Nicolas Isambert

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jean-Michel Coindre

16

object named as

Jean-Michel Coindre

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Emmanuelle Bompas

9

object named as

Emmanuelle Bompas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

François Bertucci

8

object named as

François Bertucci

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Olivier Collard

7

object named as

Olivier Collard

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Florence Duffaud

5

object named as

Florence Duffaud

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gauthier Decanter

14

object named as

Gauthier Decanter

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Antoine Italiano

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Maria Rios

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Binh Bui

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Patrick Zintl

17

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nadia Badri

18

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

6 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Emerging drugs for the treatment of soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

7 July 2018

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-64

21 January 2018

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-64

21 January 2018

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-64

21 January 2018

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-64

21 January 2018

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-64

21 January 2018

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

27 October 2018

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3620689

27 October 2018

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23388156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-64

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34578850&oldid=2196818980"